Equity Overview
Price & Market Data
Price: $19.13
Daily Change: -$1.11 / 5.78%
Daily Range: $18.29 - $20.68
Market Cap: $483,845,344
Daily Volume: 369,218
Performance Metrics
1 Week: -0.44%
1 Month: 20.81%
3 Months: 8.66%
6 Months: 0.66%
1 Year: 0.66%
YTD: 0.66%
Details
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.